Antithrombin III-independent effect of depolymerized holothurian glycosaminoglycan (DHG) on acute thromboembolism in mice

Thrombosis and Haemostasis

Volumn 77, Issue 2, 1997, Pages 399-402

  Nagase, Hideki ^b   Kitazato, Keiko T ^b   Sasaki, Eiji ^b   Hattori, Masahiko ^b   Kitazato, Kenji ^a   Saito, Hidehiko ^b  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9A; DERMATAN SULFATE; GLYCOSAMINOGLYCAN; HEPARIN; HEPARIN COFACTOR II; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN;

ANIMAL EXPERIMENT; ANTICOAGULATION; ANTITHROMBIN III DEFICIENCY; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; THROMBOEMBOLISM;

EID: 0031058101     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1655975     Document Type: Article

References (25)

1. Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 248: 6490-505.
2. Damus PS, Hicks M, Rosenberg RD. Anticoagulant action of heparin. Nature 1973; 246: 355-7.
3. Holmer E, Soderstrom G, Andersson LO. Effect of heparin in antithrombin III depleted plasma. Thromb Haemost 1979; 42: 9.
4. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516-30.
5. Spero JA, Lewis JH, Hasiba U. Disseminated intravascular coagulation. Findings in 346 patients. Thromb Haemost 1980; 43: 28-33.
6. Kauffmann RH, Veltkamp JJ, van Tilburg NH, van Es LA. Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. Am J Med 1978; 65: 607-13.
7. Marciniak E, Gockerman J. Heparin-induced decrease in circulating antithrombin III. Lancet 1977; ii: 581-4.
8. Schipper HG, Jenkins CP, Kahle LH, ten Cate JW. Antithrombin III transfusion in disseminated intravascular coagulation. Lancet 1978; 22: 854-6.
9. Lechner K, Kyrle PA. Antithrombin III concentrates - are they clinical useful? Thromb Haemost 1995; 73: 340-8.
10. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17.
11. Tollefsen DM, Perka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-6.
12. Suzuki N, Kitazato K, Takamatsu J, Saito H. Antithrombotic and anticoagulant activity of depolymerized fragment of the glycosaminoglycan extracted from Stichopus japonicus Selenka. Thromb Haemost 1991; 65: 369-73.
13. Nagase H, Enjyoji K, Minamiguchi, K, Kitazato TK, Kitazato K, Saito H, Kato H. Depolymerized holothurian glycosaminoglycan with novel anticoagulant actions: Antithrombin III-and heparin cofactor II-independent inhibition of factor X activation by factor IXa-factor VIIIa complex and heparin cofactor II-dependent inhibition of thrombin. Blood 1995; 85: 1527-34.
14. Kitazato K, Kitazato TK, Nagase H, Minamiguchi K. DHG, a new depolymerized holothurian glycosaminoglycan, exerts an antithrombotic effect with less bleeding than unfractionated or low molecular weight heparin, in rats. Thromb Res 1996; 84: 111-20.
15. Yoshida K, Minami Y, Nemoto H, Numata K, Yamanaka E. Structure of DHG, a depolymerized glycosaminoglycan from sea cucumber, Stichopus japonicus. Tetrahedron Lett 1992; 33: 4959-62.
16. Tran TH, Lämmle B, Zbinden B, Duckert F. Heparin cofactor II: Purification and antibody production. Thromb Haemost 1986; 55: 19-23.
17. Curtis JE, Helgerson SL, Parker ET, Lollar P. Isolation and characterization of thrombin-activated human factor VIII. J Biol Chem 1994; 269: 6246-51.
18. Kumada T, Dittman WA, Majerus PW. A role for thrombomodulin in the pathogenesis of thrombin-induced thromboembolism in mice. Blood 1987; 71: 728-33.
19. Koide T. Isolation and characterization of antithrombin III from human, porcine and rabbit plasma, and rat serum. J Biochem 1979; 86: 1841-50.
20. Kumada T, Abiko Y. Preparation and immunological determination of rat antithrombin III. Thromb Res 1980; 17: 789-99.
21. Lamontagne L, Gauldie J. Ontogeny of mouse and rat antithrombin III. Thromb Res 1980; 20: 417-24.
22. Odegard OR, Lie M, Abildgaard U. Antifactor Xa activity measured with amidolytic methods. Haemostas 1976; 5: 265-75.
23. Kumada T, Abiko Y. Comparative study on heparin and a synthetic thrombin inhibitor No. 805 (MD-805) in experimental antithrombin III-deficient animals. Thromb Res 1981; 24: 285-98.
24. Aoki Y, Ohishi R, Takai R, Matsuzaki O, Mohri M, Saitoh K, Gomi K, Sugihara T, Kiyota T, Yamamoto S, Ishida T, Maruyama I. Effects of recombinant human soluble thrombomodulin (rhs-TM) on a rat model of disseminated intravascular coagulation with decreased levels of plasma antithrombin III. Thromb Haemost 1994; 71: 452-5.
25. Sandset PM, Andersson TR. Coagulation inhibitor levels in pneumonia and stroke: changes due to consumption and acute phase reaction. J Intern Med 1989; 225: 311-6.